Next Article in Journal
Structural Elucidation of Rift Valley Fever Virus L Protein towards the Discovery of Its Potential Inhibitors
Previous Article in Journal
A Review of the Phytochemistry and Pharmacological Properties of the Genus Arrabidaea
 
 
Article

Evaluation of Toxic Properties of New Glycopeptide Flavancin on Rats

1
Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia
2
Organic Chemistry Department, Mendeleyev University of Chemical Technology of Russia, 9 Miusskaya Square, 125047 Moscow, Russia
*
Author to whom correspondence should be addressed.
Academic Editor: Jesus Jimenez-Barbero
Pharmaceuticals 2022, 15(6), 661; https://doi.org/10.3390/ph15060661
Received: 20 April 2022 / Revised: 12 May 2022 / Accepted: 23 May 2022 / Published: 25 May 2022
(This article belongs to the Section Pharmacology)
Glycopeptide antibiotics have side effects that limit their clinical use. In view of this, the development of glycopeptides with improved chemotherapeutic properties remains the main direction in the search for new antibacterial drugs. The objective of this study was to evaluate the toxicological characteristics of new semi-synthetic glycopeptide flavancin. Acute and chronic toxicity of antibiotic was evaluated in Wistar rats. The medium lethal dose (LD50) and the maximum tolerated doses (MTD) were calculated by the method of Litchfield and Wilcoxon. In the chronic toxicity study, the treatment regimen consisted of 15 daily intraperitoneal injections using two dosage levels: 6 and 10 mg/kg/day. Total doses were equivalent to MTD or LD50 of flavancin, respectively. The study included assessment of the body weight, hematological parameters, blood biochemical parameters, urinalysis, and pathomorphological evaluation of the internal organs. The results of the study demonstrated that no clinical-laboratory signs of toxicity were found after 15 daily injections of flavancin at a total dose close to the MTD or LD50. The pathomorphological study did not reveal any lesions on the organ structure of animals after low-dose administration of flavancin. Thus, flavancin favorably differs in terms of toxicological properties from the glycopeptides currently used in the clinic. View Full-Text
Keywords: semi-synthetic glycopeptide antibiotics; vancomycin; eremomycin; flavancin; acute toxicity; chronic toxicity; rats semi-synthetic glycopeptide antibiotics; vancomycin; eremomycin; flavancin; acute toxicity; chronic toxicity; rats
Show Figures

Figure 1

MDPI and ACS Style

Treshchalin, M.I.; Polozkova, V.A.; Moiseenko, E.I.; Treshalina, H.M.; Shchekotikhin, A.E.; Pereverzeva, E.R. Evaluation of Toxic Properties of New Glycopeptide Flavancin on Rats. Pharmaceuticals 2022, 15, 661. https://doi.org/10.3390/ph15060661

AMA Style

Treshchalin MI, Polozkova VA, Moiseenko EI, Treshalina HM, Shchekotikhin AE, Pereverzeva ER. Evaluation of Toxic Properties of New Glycopeptide Flavancin on Rats. Pharmaceuticals. 2022; 15(6):661. https://doi.org/10.3390/ph15060661

Chicago/Turabian Style

Treshchalin, Michael I., Vasilisa A. Polozkova, Elena I. Moiseenko, Helen M. Treshalina, Andrey E. Shchekotikhin, and Eleonora R. Pereverzeva. 2022. "Evaluation of Toxic Properties of New Glycopeptide Flavancin on Rats" Pharmaceuticals 15, no. 6: 661. https://doi.org/10.3390/ph15060661

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop